Valuation: DiaMedica Therapeutics Inc.

Market Cap 616M 434M 387M 360M 327M 41.06B 627M 4.32B 1.69B 21.43B 1.63B 1.59B 68.56B P/E 2026 *
-9.9x
P/E 2027 * -9.95x
Enterprise Value 616M 434M 387M 360M 327M 41.06B 627M 4.32B 1.69B 21.43B 1.63B 1.59B 68.56B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
56.63%
Yield 2026 *
-
Yield 2027 * -
1 day+4.96%
1 week+0.37%
Current month-2.78%
1 month+23.12%
3 months+5.24%
6 months+22.19%
Current year+1.01%
1 week 7.61
Extreme 7.61
8.34
1 month 6.68
Extreme 6.675
8.63
Current year 5.24
Extreme 5.245
9.04
1 year 5.24
Extreme 5.245
10.42
3 years 2.05
Extreme 2.05
10.42
5 years 1.12
Extreme 1.12
10.42
10 years 1.12
Extreme 1.12
13.77
Manager TitleAgeSince
Chief Executive Officer 54 2009-12-31
Director of Finance/CFO 60 2018-03-31
Chief Tech/Sci/R&D Officer 60 2025-08-10
Director TitleAgeSince
Director/Board Member 70 2010-08-09
Chairman 54 2008-03-31
Chairman 61 2024-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/10/26 Free

Chief Executive Officer

60,200 0.1117%
6/1/26 Free

Director

40,412 -
6/1/26 Free

Chief Financial Officer

162,000 -
Change 5-day change 1-year change 3-year change Capi.($)
+4.96%+0.37%+14.04%+292.20% 413M
+0.21%-4.63%+55.34%+71.32% 68.92B
+1.66%+7.51%+8.12%+60.04% 51.9B
+3.14%+7.17%+12.48%+44.42% 48.73B
+3.45%+4.70%+33.44%+35.96% 43.13B
-2.20%+0.61%+281.88%+532.76% 41.48B
+6.43%+6.84%+18.32%+109.23% 39.96B
+1.28%+1.39%+11.69%+45.10% 30.6B
-2.21%-10.09%+35.34%-0.94% 26.01B
+1.74%-2.02%-13.55%-12.92% 22.27B
Average +1.85%-0.81%+45.71%+117.72% 37.34B
Weighted average by Cap. +1.58%-0.25%+52.73%+105.51%

Financials

2026 *2027 *
Net sales - -
Net income -63.02M -44.39M -39.62M -36.83M -33.5M -4.2B -64.16M -442M -173M -2.19B -167M -163M -7.02B -71.35M -50.26M -44.86M -41.69M -37.92M -4.76B -72.63M -501M -196M -2.48B -189M -185M -7.95B
Net Debt - -
Projected Income Statement - Annual - DiaMedica Therapeutics Inc.
Logo DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.
Employees
35
Date Price Change Volume
26-10-15 US$8.040 +4.96% 303,894
26-10-14 US$7.660 -2.05% 286,961
26-10-13 US$7.820 -4.63% 256,052
26-10-12 US$8.200 -1.56% 185,593
26-10-09 US$8.330 +4.00% 170,151
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - DiaMedica Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
8.040USD
Average target price
15.50USD
Spread / Average Target
+92.79%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - DiaMedica Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. DMAC Stock